Abstract
After a decade of work to address cellular uptake, the principal obstacle to RNAi-based therapeutics, there is now well-deserved, renewed optimism about RNAi-based drugs. Phase I and II studies have shown safe, strong, and durable-gene knockdown (80–90 %, lasting for a month after a single injection) and/or clinical benefit in treating several liver pathologies. Although promising, these studies have also highlighted the need for robust delivery techniques to develop RNAi therapeutics for treating other organ systems and diseases. Conjugation of siRNAs to cell-specific, synthetic RNA ligands (aptamers) is being proposed as a viable solution to this problem. While encouraging, the extended use of RNA aptamers as a delivery tool for siRNAs awaits the identification of RNA aptamer sequences capable of targeting and entering the cytoplasm of many different cell types. We describe a cell-based selection process for the rapid identification and characterization of RNA aptamers suited for delivering siRNA drugs into the cytoplasm of target cells. This process, termed “cell-internalization SELEX (Systematic Evolution of Ligands by Exponential Enrichment),” entails the combination of multiple sophisticated technologies, including cell culture-based SELEX procedures, next-generation sequencing (NGS), and novel bioinformatics tools.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Keefe AD, Pai S, Ellington A (2010) Aptamers as therapeutics. Nat Rev Drug Discov 9:537–550
Thiel KW, Giangrande PH (2009) Therapeutic applications of DNA and RNA aptamers. Oligonucleotides 19:209–222
Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AP (2006) Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 5:123–132
Apte RS (2008) Pegaptanib sodium for the treatment of age-related macular degeneration. Expert Opin Pharmacother 9:499–508
Sundaram P, Kurniawan H, Byrne ME, Wower J (2013) Therapeutic RNA aptamers in clinical trials. Eur J Pharm Sci 48:259–271
Thiel KW, Giangrande PH (2010) Intracellular delivery of rna-based therapeutics using aptamers. Ther Deliv 1:849–861
Cerchia L, Giangrande PH, McNamara JO, de Franciscis V (2009) Cell-specific aptamers for targeted therapies. Methods Mol Biol 535:59–78
Zhou J, Rossi JJ (2011) Cell-specific aptamer-mediated targeted drug delivery. Oligonucleotides 21:1–10
Zhou J, Bobbin ML, Burnett JC, Rossi JJ (2012) Current progress of RNA aptamer-based therapeutics. Front Genet 3:234
Kanwar JR, Roy K, Kanwar RK (2011) Chimeric aptamers in cancer cell-targeted drug delivery. Crit Rev Biochem Mol Biol 46:459–477
Sundaram P, Wower J, Byrne ME (2012) A nanoscale drug delivery carrier using nucleic acid aptamers for extended release of therapeutic. Nanomedicine 8:1143–1151
McNamara JO II, Andrechek ER, Wang Y, Viles KD, Rempel RE, Gilboa E, Sullenger BA, Giangrande PH (2006) Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 24:1005–1015
Pastor F, Kolonias D, Giangrande PH, Gilboa E (2010) Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay. Nature 465:227–230
Dassie JP, Liu XY, Thomas GS, Whitaker RM, Thiel KW, Stockdale KR, Meyerholz DK, McCaffrey AP, McNamara JO II, Giangrande PH (2009) Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 27:839–849
Wheeler LA, Vrbanac V, Trifonova R, Brehm MA, Gilboa-Geffen A, Tanno S, Greiner DL, Luster AD, Tager AM, Lieberman J (2013) Durable knockdown and protection from hiv transmission in humanized mice treated with gel-formulated cd4 aptamer-siRNA chimeras. Mol Ther 21:1378–1389
Neff CP, Zhou J, Remling L, Kuruvilla J, Zhang J, Li H, Smith DD, Swiderski P, Rossi JJ, Akkina R (2011) An aptamer-siRNA chimera suppresses hiv-1 viral loads and protects from helper cd4(+) t cell decline in humanized mice. Sci Transl Med 3:66ra66
Ni X, Zhang Y, Ribas J, Chowdhury WH, Castanares M, Zhang Z, Laiho M, DeWeese TL, Lupold SE (2011) Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. J Clin Invest 121:2383–2390
Ellington AD, Szostak JW (1990) In vitro selection of RNA molecules that bind specific ligands. Nature 346:818–822
Tuerk C, Gold L (1990) Systematic evolution of ligands by exponential enrichment: Rna ligands to bacteriophage t4 DNA polymerase. Science 249:505–510
Thiel KW, Hernandez LI, Dassie JP, Thiel WH, Liu X, Stockdale KR, Rothman AM, Hernandez FJ, McNamara JO II, Giangrande PH (2012) Delivery of chemo-sensitizing siRNAs to her2+-breast cancer cells using RNA aptamers. Nucleic Acids Res 40:6319–6337
Thiel WH, Bair T, Peek AS, Liu X, Dassie J, Stockdale KR, Behlke MA, Miller FJ Jr, Giangrande PH (2012) Rapid identification of cell-specific, internalizing RNA aptamers with bioinformatics analyses of a cell-based aptamer selection. PLoS One 7:e43836
Huang YZ, Hernandez FJ, Gu B, Stockdale KR, Nanapaneni K, Scheetz TE, Behlke MA, Peek AS, Bair T, Giangrande PH, McNamara JO II (2012) RNA aptamer-based functional ligands of the neurotrophin receptor, trkb. Mol Pharmacol 82:623–635
Thiel WH, Bair T, Thiel WK, Dassie JP, Rockey WM, Howell CA, Liu XY, Dupuy AJ, Huang L, Owczarzy R, Behlke MA, McNamara JO, Giangrande PH (2011) Nucleotide bias observed with a short selex RNA aptamer library. Nucleic Acid Ther 21:253–263
Meyer S, Maufort JP, Nie J, Stewart R, McIntosh BE, Conti LR, Ahmad KM, Soh HT, Thomson JA (2013) Development of an efficient targeted cell-selex procedure for DNA aptamer reagents. PLoS One 8:e71798
Reiss DJ, Howard FM, Mobley HL (2012) A novel approach for transcription factor analysis using selex with high-throughput sequencing (tfast). PLoS One 7:e42761
Zimmermann B, Gesell T, Chen D, Lorenz C, Schroeder R (2010) Monitoring genomic sequences during selex using high-throughput sequencing: neutral selex. PLoS One 5:e9169
Jagannathan V, Roulet E, Delorenzi M, Bucher P (2006) Htpselex–a database of high-throughput selex libraries for transcription factor binding sites. Nucleic Acids Res 34:D90–D94
Roulet E, Busso S, Camargo AA, Simpson AJ, Mermod N, Bucher P (2002) High-throughput selex sage method for quantitative modeling of transcription-factor binding sites. Nat Biotechnol 20:831–835
McNamara JO, Kolonias D, Pastor F, Mittler RS, Chen L, Giangrande PH, Sullenger B, Gilboa E (2008) Multivalent 4-1bb binding aptamers costimulate cd8+ t cells and inhibit tumor growth in mice. J Clin Invest 118:376–386
Sousa R, Padilla R (1995) A mutant t7 RNA polymerase as a DNA polymerase. EMBO J 14:4609–4621
Hernandez FJ, Stockdale KR, Huang L, Horswill AR, Behlke MA, McNamara JO II (2012) Degradation of nuclease-stabilized RNA oligonucleotides in mycoplasma-contaminated cell culture media. Nucleic Acid Ther 22:58–68
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this protocol
Cite this protocol
Thiel, W.H. et al. (2015). Cell-Internalization SELEX: Method for Identifying Cell-Internalizing RNA Aptamers for Delivering siRNAs to Target Cells. In: Sioud, M. (eds) RNA Interference. Methods in Molecular Biology, vol 1218. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-1538-5_11
Download citation
DOI: https://doi.org/10.1007/978-1-4939-1538-5_11
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-1537-8
Online ISBN: 978-1-4939-1538-5
eBook Packages: Springer Protocols